Crossmark

Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan

Published Online: 2020-06-10

Published Print: 2020-12

Authors

Kashiwagi, Kenji http://orcid.org/0000-0001-8506-8503
Chono, Eriko

Koesters, Sarah

Yap, Poh Sin
Funding

Funding for this research was provided by:

Novartis Pharma KK
License Information

Text and Data Mining valid from 2020-06-10

Version of Record valid from 2020-06-10
More Information

Article History

Received: 24 March 2020

Accepted: 5 June 2020

First Online: 10 June 2020

Ethics approval and consent to participate

: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Ethical Review Board of the Specified Nonprofit Organization clinical research promotion network Japan (CR-IRB-0052).This study acquired secondary data from a medical claims database, written informed consent from patients was not required.

: Not applicable.

: KK has no financial interest to disclose; EC is employee of Novartis Pharma K.K; SK and PSY are employees of Novartis.

Document is current